Monoclonal Antibody Therapy Enhancers (MATEs) are multi-functional molecules composed of a therapeutic antibody covalently linked to one or more small molecule immune cell binders developed by Kleo.

HOW MATEs WORK

MATEs are similar in concept to an antibody drug conjugate (ADC) which links a cytotoxic drug to a monoclonal antibody. In our case, we engage the patient’s own immune cells to mediate tumor cell destruction.

PLATFORM ADVANTAGES

MATEs have the potential to increase efficacy by adding additional mechanisms of action (e.g. T cell engagement) to therapeutic antibodies while maintaining their previous functionality. This format does not require altering established manufacturing and purification techniques, saving development time for next generation therapeutics.